| scholarly article | Q13442814 |
| P2093 | author name string | D N Hayes | |
| L Makowski | |||
| P2860 | cites work | Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer | Q58890533 |
| PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration | Q59313170 | ||
| Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers syndrome | Q73157991 | ||
| Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers | Q73603262 | ||
| Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types | Q74480207 | ||
| Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas | Q77827931 | ||
| A case of pulmonary adenocarcinoma accompanied by superior vena caval thrombosis in a patient with peutz-jeghers syndrome | Q78461311 | ||
| LKB1 protein expression in human breast cancer | Q79755572 | ||
| Bronchioloalveolar carcinoma: a new cancer in Peutz-Jeghers syndrome | Q81245439 | ||
| [Non-small cell bronchogenic carcinoma and Peutz-Jeghers syndrome] | Q81789200 | ||
| AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling | Q22241925 | ||
| AMP-activated kinase regulates cytoplasmic HuR. | Q24537360 | ||
| COSMIC 2005 | Q24652464 | ||
| A serine/threonine kinase gene defective in Peutz-Jeghers syndrome | Q28119198 | ||
| Celecoxib for the prevention of sporadic colorectal adenomas | Q28200368 | ||
| Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung | Q28208680 | ||
| Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene | Q28250528 | ||
| Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase | Q28258611 | ||
| Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines | Q28275084 | ||
| Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis | Q28300857 | ||
| A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome | Q28307804 | ||
| The tuberous sclerosis complex | Q29619128 | ||
| LKB1 modulates lung cancer differentiation and metastasis | Q30080027 | ||
| Molecular analysis of the TSC1 gene in adenocarcinoma of the lung | Q31127198 | ||
| Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis | Q34009330 | ||
| Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis | Q34156001 | ||
| LKB1-dependent signaling pathways | Q34535140 | ||
| Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. | Q34547049 | ||
| Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance | Q34551203 | ||
| Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. | Q34551816 | ||
| Frequency and spectrum of cancers in the Peutz-Jeghers syndrome | Q34567595 | ||
| 5'-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer | Q35360684 | ||
| Loss of Heterozygosity on Chromosomes 9q and 16p in Atypical Adenomatous Hyperplasia Concomitant with Adenocarcinoma of the Lung | Q35788341 | ||
| LKB1 somatic mutations in sporadic tumors | Q35793276 | ||
| Prevalence and specificity of LKB1 genetic alterations in lung cancers | Q36277692 | ||
| Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts | Q36639457 | ||
| PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. | Q36752013 | ||
| LKB1 gene mutations in Japanese lung cancer patients. | Q40091083 | ||
| LKB1/STK11 suppresses cyclooxygenase-2 induction and cellular invasion through PEA3 in lung cancer. | Q40243365 | ||
| LKB1 protein expression in the evolution of glandular neoplasia of the lung. | Q44369413 | ||
| Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies | Q46803174 | ||
| mTOR: the mammalian target of replication | Q46803176 | ||
| Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression | Q46868532 | ||
| Expression of LKB1 and PTEN tumor suppressor genes during mouse embryonic development | Q52176250 | ||
| Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain | Q53401422 | ||
| Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer | Q53545682 | ||
| Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome | Q57240072 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| lung cancer | Q47912 | ||
| lung neoplasm | Q15124212 | ||
| P304 | page(s) | 683-688 | |
| P577 | publication date | 2008-08-19 | |
| 2008-09-02 | |||
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Role of LKB1 in lung cancer development | |
| P478 | volume | 99 |
| Q37728090 | A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer |
| Q35185119 | Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. |
| Q39517661 | Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. |
| Q35556966 | Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy |
| Q88135517 | CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo |
| Q54415412 | CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer |
| Q60395558 | Chemistry and Pharmacology of Rapamycin and Its Derivatives |
| Q57990927 | Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning |
| Q39350353 | Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1. |
| Q33604979 | Enhancing mTOR-targeted cancer therapy |
| Q48546803 | Fenofibrate prevents skeletal muscle loss in mice with lung cancer. |
| Q30578909 | Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. |
| Q30241069 | From obesity to cancer: a review on proposed mechanisms |
| Q39153676 | Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers |
| Q33721668 | Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells |
| Q38057476 | KRAS Mutations in Lung Cancer |
| Q36978341 | LKB1 Controls Human Bronchial Epithelial Morphogenesis through p114RhoGEF-Dependent RhoA Activation |
| Q37383513 | LKB1 and AMP-activated protein kinase control of mTOR signalling and growth |
| Q39101598 | LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas |
| Q37599925 | Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. |
| Q34430735 | Lovastatin Induces Multiple Stress Pathways Including LKB1/AMPK Activation That Regulate Its Cytotoxic Effects in Squamous Cell Carcinoma Cells |
| Q36368238 | Negative Regulation of AMP-activated Protein Kinase (AMPK) Activity by Macrophage Migration Inhibitory Factor (MIF) Family Members in Non-small Cell Lung Carcinomas |
| Q33576271 | No association between promoter polymorphism of STK11 gene and lung cancer risk in the Korean population |
| Q34437857 | Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. |
| Q37276139 | Obesity, metabolism and the microenvironment: Links to cancer |
| Q93271394 | Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis |
| Q37571960 | Stem cells and lung cancer: future therapeutic targets? |
| Q40590335 | Structure of the 14-3-3ζ-LKB1 fusion protein provides insight into a novel ligand-binding mode of 14-3-3. |
| Q41339882 | Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials |
| Q29617506 | The LKB1-AMPK pathway: metabolism and growth control in tumour suppression |
| Q42705776 | The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss |
| Q39197659 | The Tumor Suppressor Kinase LKB1 Activates the Downstream Kinases SIK2 and SIK3 to Stimulate Nuclear Export of Class IIa Histone Deacetylases |
| Q33939369 | The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo |
| Q37983690 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment |
| Q36191321 | Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus |
| Q35915752 | ZEB1-responsive genes in non-small cell lung cancer |
Search more.